BAY 85-8501

Drug Profile

BAY 85-8501

Alternative Names: BAY 858501

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare
  • Class Bronchodilators
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bronchiectasis

Most Recent Events

  • 03 Sep 2016 Adverse events data from a phase II trial in Bronchiectasis presented at the 26th Annual Congress of the European Respiratory Society 2016 (ERS-2016)
  • 30 Jun 2014 Bayer completes a phase IIa trial in Bronchiectasis in United Kingdom, Spain, France, Germany & Italy (NCT01818544)
  • 08 Mar 2013 Phase-II clinical trials in Bronchiectasis in France, Germany & Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top